Loading...
XSHE
000963
Market cap7.06bUSD
Oct 09, Last price  
27.29CNY
1D
1.26%
1Q
-7.11%
Jan 2017
13.61%
IPO
-19.74%
Name

Huadong Medicine Co Ltd

Chart & performance

D1W1MN
XSHE:000963 chart
P/E
14.02
P/S
1.10
EPS
1.95
Div yield, %
3.45%
Shrs. gr., 5y
0.05%
Rev. gr., 5y
5.30%
Revenues
43.61b
+4.07%
3,968,250,8814,853,413,4206,016,486,1417,824,872,1648,971,836,50911,131,372,42214,579,230,37316,717,986,44418,947,379,09321,727,383,49425,379,667,50227,831,823,14730,663,374,32535,445,698,21533,683,058,75934,563,301,23237,714,587,45740,623,782,51941,905,707,38543,612,010,000
Net income
3.41b
-2.78%
96,575,827173,160,209168,609,741378,421,189317,306,761381,485,000469,927,244574,975,857756,669,4231,096,912,4351,446,591,7031,779,506,0662,267,229,1802,813,118,7052,819,861,2062,301,631,3522,499,214,3612,838,860,5463,512,104,6813,414,335,000
CFO
4.25b
+13.25%
68,380,441265,790,560344,689,663567,939,912-27,989,14416,123,655642,729,225476,977,320740,854,722658,536,2571,346,962,8031,661,118,6592,039,496,0792,001,698,1703,411,447,7463,169,757,8592,381,852,6633,929,216,6993,748,928,8794,245,604,371
Dividend
Sep 18, 20260.35 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Huadong Medicine Co., Ltd is a leading pharmaceutical enterprise based in China, primarily focused on the creation, production, and distribution of a wide variety of medicinal products. Its extensive product catalog encompasses traditional Chinese patent medicines, immunosuppressive agents, endocrine treatments, digestive system remedies, cancer therapeutics, cardiovascular medications, and antibiotics. The company also supplies medical devices and offers solutions in the field of aesthetic medicine. Noteworthy product lines include gastrointestinal agents and Active Pharmaceutical Ingredients (APIs). Beyond its core pharmaceutical activities, Huadong Medicine is involved in the manufacturing and management of both traditional Chinese and Western raw medicines, prepared formulations, and health supplements. Its operations extend to the wholesale trade of Traditional Chinese Medicine (TCM) ingredients, prepared TCM decoction pieces, and various chemical preparations, complemented by warehousing and logistical services. A significant area of focus for the company is the research, development, manufacturing, and commercialization of aesthetic medicine products. Established in 1993, Huadong Medicine Co., Ltd maintains its corporate headquarters in Hangzhou, China.

Key people

Renbo Qiu
Finance Director · since 2019
Liang Lu
Executive Chairman of the Board, General Manager · since 2025
Hui Wu
Deputy General Manager · since 2019
Zhongxing Zhang
Deputy General Manager · since 2025
Jianfei Zhang
Deputy General Manager · since 2022
Li Zhu
Deputy General Manager · since 2020
Bo Chen
Secretary of the Board · since 2009
Jiabo Dong
Director · since 2025
Wei Kang
Director · since 2016
Director · since 2025
Yang Wang
Director · since 2023
Feipeng Zhu
Director · since 2022
Liang Zhu
Director · since 2019
Jian Huang
Independent Director · since 2023
Ruwei Wang
Independent Director · since 2022
Shuzhen Wei
Independent Director · since 2025
Lixiang Xue
Independent Director · since 2025
IPO date
Jan 27, 2000
Employees
Domiciled in
CN
Incorporated in
CN
Headquarters & legal address
浙江省杭州市延安路468号1号楼1号门7、9、10楼
杭州市, ZJ 310000
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT